← Back to Clinical Trials
Recruiting NCT05862454

NCT05862454 Magnesium Injection Ensures Steroid Avoidance During Vaccine, Viremia or Immunocompromise

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05862454
Status Recruiting
Phase
Sponsor Salem Anaesthesia Pain Clinic
Condition Steroid Metabolism Disorder
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2020-07-02
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 99 Years
Study Type OBSERVATIONAL
Interventions
Magnesium

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2020-07-02 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Steroid injections are used for interventional pain management. However, their side-effect of immunosuppression may increase the risk of infections. Magnesium is an alternative anti-nociceptive injection that may be used instead of steroids. Prospective observational study of patients who received magnesium injection for interventional pain therapy, instead of steroid injection. Post-injection data collection includes numerical rating pain score, and sleep quality score. Pain is measured using the numeric pain rating scale. Sleep score is measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points is considered significant.

Eligibility Criteria

Inclusion Criteria: * adult chronic pain patients * previous interventional injection therapy * consent for interventional injection therapy * good treatment compliance * regular sleep diary * regular pain diary * informed consent for diary review * consent for clinical record quality assurance review Exclusion Criteria: * organ insufficiency * cognitive disorder * inability to provide consent * major neuropsychiatric disorder * unreliable diary * poor treatment compliance * previous adverse/allergic reactions to magnesium

Contact & Investigator

Central Contact

Olu Bamgbade, MD,FRCPC

✉ salem.painclinic@gmail.com

📞 17786286600

Principal Investigator

Olu Bamgbade, MD,FRCPC

PRINCIPAL INVESTIGATOR

Salem Anaesthesia Pain Clinic

Frequently Asked Questions

Who can join the NCT05862454 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 99 Years, studying Steroid Metabolism Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05862454 currently recruiting?

Yes, NCT05862454 is actively recruiting participants. Contact the research team at salem.painclinic@gmail.com for enrollment information.

Where is the NCT05862454 trial being conducted?

This trial is being conducted at Surrey, Canada.

Who is sponsoring the NCT05862454 clinical trial?

NCT05862454 is sponsored by Salem Anaesthesia Pain Clinic. The principal investigator is Olu Bamgbade, MD,FRCPC at Salem Anaesthesia Pain Clinic. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology